頁籤選單縮合
題 名 | 生物治療在腫瘤醫學的最新進展=Recent Advance of Biotherapy in Medical Oncology |
---|---|
作 者 | 陳博明; 楊慕華; | 書刊名 | 腫瘤護理雜誌 |
卷 期 | 1:2 2001.12[民90.12] |
頁 次 | 頁55-63 |
分類號 | 418.99 |
關鍵詞 | 生物治療; 腫瘤醫學; Biotherapy; Medical oncology; |
語 文 | 中文(Chinese) |
中文摘要 | 生物治療是指利用生物製劑去治療癌症。經過將近20年醫學界不斷的研究與發展,生物療法現在已經成為繼外科手術,放射治療,化學治療以後,第四種治療癌症的利器了。本文就目前最新發展的五種生物療法做一概廓性介紹。 賀癌停(Herceptin)單株抗體是新發展出來針對Her-2/neu基因陽性之乳癌的生物療法。無論是併用化學藥物或是單獨使用賀癌停,都有相當好的療效,副作用主要是心臟毒性,但並不嚴重。Rituximab也是新進發展出來的抗癌單株抗體,主要是針對CD20陽性的B細胞淋巴瘤有相當特異的抗癌效果。Rituximab也可合併化學藥物或是單獨使用,療效均相當不錯,且副作用輕微。介白素二號(Interleukin-2)則對於化學治療效果不佳的腎細胞癌以及惡性黑色素瘤有一定療效。微脂體包被化學藥物可效減低藥物副作用,並增加藥物的組織專一性,目前liposomal-doxorubicin對於乳癌的療效以及安全性都已被肯定。最後是癌症醫學的最新進展:血管生成抑制劑thalidomide,目前已證實對多發性骨髓瘤有一定療效,對肝癌也有部分治療效果。 |
英文摘要 | Biotherapy is a newly developed therapeutic modality against cancer, and it has been considered as the fowth? Effective treatment against malignancies after the development of surgical intervention, radiotherapy and chemotherapy. In this article, we aim to introduce the recent advance of cancer biotherapy: herceptin, rituximab, interleukin-2, liposomal-doxorubicin, and thalidomide. Herceptin is a monoclonal antibody against Her-2/neu overexpressed breast cancer, and it could be used as monotherapy, or combined with chemotherapy. Cardiotoxicity is the main concern of herceptin, but it generally acceptable. Rituximab is also a monoclonal antibody, that it could act against CD20 positive B-cell lymphoid neoplasms, and could also be given as monotherapy or combined with chemotherapy. The minimal side effect and effectiveness make rituximab a good therapeutic choice for B-cell malignanices. Interleukin-2 could act against renal cell carcinoma and malignant melanoma, which are generally considered chemo-resistant. Liposomal-doxorubicin could provide better target-specificity and lesser toxicity, and now is used for treating advanced breast cancer. Thalidominde acts as an angiogenesis inhibitor, that it has been proved to be effective in refractory multiple myeloma, and also provides some effect against late-stage hepatoma. In recent years, biotherapy becomes an alternative choice in cancer treatment, and it should be a mainstay of cancer treatment in the future because of its safety and effectiveness. |
本系統中英文摘要資訊取自各篇刊載內容。